Literature DB >> 18381193

High-performance liquid chromatography accelerator mass spectrometry: correcting for losses during analysis by internal standardization.

G Lappin1, M Simpson, Y Shishikura, C Garner.   

Abstract

A method was developed to account for analytical losses of (14)C-analyte when determining the concentration in biological samples using chromatographic separation and analysis by accelerator mass spectrometry. From the equations of J. Vogel and A.H. Love (in: A.L. Burlingame (Ed.), Methods in Enzymology, Academic Press, New York, 2005), new equations were derived to describe the isotopic dilution of a chromatographically isolated (14)C-analyte. The analytical recovery for each sample was determined by the use of the UV response for nonlabeled analyte, as an internal standard against a standard curve. The slope of the curve was substituted into the equations to provide a method of accurately determining the analyte concentration.

Mesh:

Year:  2008        PMID: 18381193     DOI: 10.1016/j.ab.2008.03.026

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  4 in total

1.  Predicting drug candidate victims of drug-drug interactions, using microdosing.

Authors:  Marie Croft; Brendan Keely; Ian Morris; Lan Tann; Graham Lappin
Journal:  Clin Pharmacokinet       Date:  2012-04-01       Impact factor: 6.447

Review 2.  Accelerator mass spectrometry-enabled studies: current status and future prospects.

Authors:  Ali Arjomand
Journal:  Bioanalysis       Date:  2010-03       Impact factor: 2.681

Review 3.  Microdosing and drug development: past, present and future.

Authors:  Graham Lappin; Robert Noveck; Tal Burt
Journal:  Expert Opin Drug Metab Toxicol       Date:  2013-04-04       Impact factor: 4.481

4.  A microdose study of ¹⁴C-AR-709 in healthy men: pharmacokinetics, absolute bioavailability and concentrations in key compartments of the lung.

Authors:  G Lappin; M J Boyce; T Matzow; S Lociuro; M Seymour; S J Warrington
Journal:  Eur J Clin Pharmacol       Date:  2013-06-06       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.